Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for MGNX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -40.75M
March 31, 2026 -35.81M
December 31, 2025 43.02M
September 30, 2025 -30.19M
June 30, 2025 -46.98M
March 31, 2025 -46.89M
December 31, 2024 -38.41M
September 30, 2024 60.16M
June 30, 2024 -44.48M
March 31, 2024 -45.64M
December 31, 2023 -28.04M
September 30, 2023 -35.25M
June 30, 2023 -2.089M
March 31, 2023 -12.83M
December 31, 2022 29.32M
September 30, 2022 -9.422M
June 30, 2022 -49.16M
March 31, 2022 -57.70M
December 31, 2021 -54.31M
September 30, 2021 -14.80M
June 30, 2021 -45.69M
March 31, 2021 -29.04M
December 31, 2020 -5.533M
September 30, 2020 -25.68M
June 30, 2020 -36.55M
Date Value
March 31, 2020 -44.14M
December 31, 2019 -38.04M
September 30, 2019 -17.39M
June 30, 2019 -48.84M
March 31, 2019 -30.00M
December 31, 2018 -27.23M
September 30, 2018 -36.98M
June 30, 2018 -57.73M
March 31, 2018 -31.30M
December 31, 2017 111.84M
September 30, 2017 -31.35M
June 30, 2017 -30.76M
March 31, 2017 -35.33M
December 31, 2016 -28.33M
September 30, 2016 49.79M
June 30, 2016 -33.23M
March 31, 2016 -31.91M
December 31, 2015 -23.86M
September 30, 2015 -7.934M
June 30, 2015 -25.46M
March 31, 2015 43.59M
December 31, 2014 -20.16M
September 30, 2014 -14.44M
June 30, 2014 -4.150M
March 31, 2014 5.886M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 3.573B
Xencor, Inc. -55.66M
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M